BIOMAT Database Logo BIOMAT Database Logo

Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group. 1994

S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
Holy Cross Hospital, Salt Lake City, Utah.

OBJECTIVE To determine the benefits of switching to didanosine compared with continuing zidovudine among patients infected with human immunodeficiency virus (HIV) who have previously used zidovudine and have signs of clinical deterioration. METHODS Randomized, double-blind, two-armed, parallel, comparative clinical trial with a blinded, compassionate crossover provision at 12 weeks. METHODS Outpatient clinics at 19 tertiary care medical centers. METHODS 312 patients infected with HIV who had received zidovudine for 6 months or more, had CD4 cell counts of 300/mm3 or less, and had signs of clinical deterioration within 12 weeks before study entry. METHODS Peroral didanosine tablets (600 mg/d adjusted for weight, "high dose") or zidovudine capsules (600 mg/d). METHODS Primary study end points were death, a new acquired immunodeficiency syndrome (AIDS)--defining event, or the combination of two new or recurrent HIV-related diagnoses with a 50% decrease in CD4 cells. RESULTS Switching to didanosine was associated with fewer end points than continuing zidovudine (relative risk [RR] for zidovudine:didanosine = 1.5; 95% Cl, 1.1 to 2.0). This benefit was consistent across subgroups of patients with either AIDS-related complex or AIDS and was most apparent among those with a CD4 count at entry of 100/mm3 or more (RR = 2.2; Cl, 1.1 to 4.4). CONCLUSIONS This study shows a positive treatment effect for switching from zidovudine to didanosine among patients with either AIDS-related complex or AIDS and validates the common practice of using clinical signs or a decrease in the CD4 count as an indication for changing therapy.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000386 AIDS-Related Complex A prodromal phase of infection with the human immunodeficiency virus (HIV). Laboratory criteria separating AIDS-related complex (ARC) from AIDS include elevated or hyperactive B-cell humoral immune responses, compared to depressed or normal antibody reactivity in AIDS; follicular or mixed hyperplasia in ARC lymph nodes, leading to lymphocyte degeneration and depletion more typical of AIDS; evolving succession of histopathological lesions such as localization of Kaposi's sarcoma, signaling the transition to the full-blown AIDS. ARC,Lymphadenopathy Syndrome,AIDS Related Complex,Complex, AIDS-Related,Lymphadenopathy Syndromes,Syndrome, Lymphadenopathy,Syndromes, Lymphadenopathy

Related Publications

S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
October 1995, Annals of internal medicine,
S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
June 1996, Annals of internal medicine,
S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.
March 1998, JAMA,
S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
August 1996, Annals of internal medicine,
S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
[Zidovudine plus didanosine in HIV infected asymptomatic patients previously treated with zidovudine].
January 1998, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion,
S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.
August 1996, Lancet (London, England),
S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
HIV/AIDS in African children: the Bristol-Myers Squibb Foundation and Baylor response.
July 2012, Health affairs (Project Hope),
S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
The Alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. Alpha International Coordinating Committee.
July 1996, AIDS (London, England),
S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
August 1994, Annals of internal medicine,
S L Spruance, and A T Pavia, and D Peterson, and A Berry, and R Pollard, and T F Patterson, and I Frank, and S C Remick, and M Thompson, and R D MacArthur, and G E Morey, and C H Ramirez-Ronda, and B M Bernstein, and D E Sweet, and L Crane, and E A Peterson, and C T Pachucki, and S L Green, and J Brand, and A Rios, and L M Dunkle, and A Cross, and M J Brown, and P Ingraham, and R Gugliotti, and A H Schindzielorz, and L Smaldone
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
December 1997, Antiviral therapy,
Copied contents to your clipboard!